A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Phase of Trial: Phase II/III
Latest Information Update: 17 Oct 2016
At a glance
- Drugs Avacincaptad pegol (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors OphthoTech Corporation
- 04 May 2016 According to an OphthoTech Corporation media release, the first patient was dosed during the first quarter of 2016.
- 29 Jan 2016 Status changed from planning to recruiting according to an Ophthotech Corporation media release.
- 05 Nov 2015 According to an Ophthotech Corporation media release, this trial is expected to begin in the end of 2015.